Karen H. Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karen H. Lu has a total of 405 co-authors. Here are the top co-authors by number of shared publications:
- Shannon Neville Westin
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
51 shared publications - Barrett C. Lawson
Department of Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
44 shared publications - Pamela T. Soliman
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
44 shared publications - Amir Anthony Jazaeri
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
43 shared publications - Ying Yuan
The University of Texas MD Anderson Cancer Center, Houston, TX
41 shared publications - David M. Gershenson
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
37 shared publications
Latest Publications
- 29 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Facilitated Cascade Genetic Testing for Relatives of Individuals With BRCA1/2 Pathogenic Variants: A Randomized Controlled Trial
PURPOSE: Despite the potential for substantial public health impact of cascade genetic testing (CGT), few at-risk relatives complete testing. We compared facilitated CGT with standard of care. METHODS: Probands with newly diagnosed BRCA1/2 germline pathogenic variants were cluster-randomized to a facilitated cascade testing intervention or standard care. Random assignment occurred at the proband level and was stratified by personal cancer history, the number of first-degree relatives (FDRs; 1-2 v ≥3), and time since genetic testing (≤6 months v >6-12 months). Adult FDRs without prior testing per self-report were enrolled. The intervention included navigation support and access to genetic testing services; control FDRs received a letter, consistent with standard clinical practice. Free germline genetic testing was available to all FDRs regardless of arm assignment. The primary outcome was completion of genetic testing at 6 months, compared using a two-sided Cochran-Mantel-Haenszel test. RESULTS: Among 151 probands with BRCA1 (52%) or BRCA2 (48%) pathogenic variants, 72% had a prior cancer diagnosis. Probands were randomly assigned, with 142 and 144 FDRs assigned to the intervention and control arms, respectively. At 6 months, genetic testing uptake was significantly higher among FDRs in the intervention group compared with the control group (73.2% [adjusted 95% CI, 64.4 to 82.1] v 50.7% [adjusted 95% CI, 41.0 to 60.4]; P < .001). By 18 months, 90% of intervention FDRs completed genetic testing. Among 206 FDRs who completed testing, 95 (46%) were found to have a pathogenic or likely pathogenic variant; of these, 82 (86%) carried the familial variant. CONCLUSION: In this randomized trial, facilitated CGT significantly increased genetic testing uptake among FDRs of probands with BRCA 1/2 pathogenic variants compared with standard care.
- 29 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Facilitated Cascade Genetic Testing for Relatives of Individuals With BRCA1/2 Pathogenic Variants: A Randomized Controlled Trial
PURPOSE: Despite the potential for substantial public health impact of cascade genetic testing (CGT), few at-risk relatives complete testing. We compared facilitated CGT with standard of care. METHODS: Probands with newly diagnosed BRCA1/2 germline pathogenic variants were cluster-randomized to a facilitated cascade testing intervention or standard care. Random assignment occurred at the proband level and was stratified by personal cancer history, the number of first-degree relatives (FDRs; 1-2 v ≥3), and time since genetic testing (≤6 months v >6-12 months). Adult FDRs without prior testing per self-report were enrolled. The intervention included navigation support and access to genetic testing services; control FDRs received a letter, consistent with standard clinical practice. Free germline genetic testing was available to all FDRs regardless of arm assignment. The primary outcome was completion of genetic testing at 6 months, compared using a two-sided Cochran-Mantel-Haenszel test. RESULTS: Among 151 probands with BRCA1 (52%) or BRCA2 (48%) pathogenic variants, 72% had a prior cancer diagnosis. Probands were randomly assigned, with 142 and 144 FDRs assigned to the intervention and control arms, respectively. At 6 months, genetic testing uptake was significantly higher among FDRs in the intervention group compared with the control group (73.2% [adjusted 95% CI, 64.4 to 82.1] v 50.7% [adjusted 95% CI, 41.0 to 60.4]; P < .001). By 18 months, 90% of intervention FDRs completed genetic testing. Among 206 FDRs who completed testing, 95 (46%) were found to have a pathogenic or likely pathogenic variant; of these, 82 (86%) carried the familial variant. CONCLUSION: In this randomized trial, facilitated CGT significantly increased genetic testing uptake among FDRs of probands with BRCA 1/2 pathogenic variants compared with standard care.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women
Supplemental Table 2 shows the weighted prevalence of LNG-IUS use by different sociodemographic characteristics as stratified by race/ethnic groups.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women
Supplemental Table 2 shows the weighted prevalence of LNG-IUS use by different sociodemographic characteristics as stratified by race/ethnic groups.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women
Supplemental Table 1 shows the sociodemographic and medical history characteristics of the NSFG sample as stratified by race/ethnic groups.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women
Supplemental Table 1 shows the sociodemographic and medical history characteristics of the NSFG sample as stratified by race/ethnic groups.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women
Supplemental Table 3 shows the association of demographic and health predictors on current LNG-IUS use as stratified by race/ethnic groups.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women
Supplemental Table 3 shows the association of demographic and health predictors on current LNG-IUS use as stratified by race/ethnic groups.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women
Levonorgestrel-releasing intrauterine system (LNG-IUS) use is approved by the FDA for contraception and heavy menorrhagia. More importantly, it effectively treats endometrial hyperplasia, a precursor to endometrial cancer. Therefore, LNG-IUS use is associated with potential endometrial cancer risk reduction, but current use patterns in the United States are unknown. We analyzed LNG-IUS use prevalence among women ages 18 to 50 years using a weighted statistical analysis of the 2017 to 2019 National Survey of Family Growth. Summary statistics were stratified by race and ethnic group and known endometrial cancer sociodemographic and health risk factors and assessed statistically with bivariate Rao–Scott χ2 tests. A multivariable logistic regression model was developed to explore LNG-IUS use predictors. Current LNG-IUS use in the United States was 6.9% [95% confidence interval (CI), 5.9%–8.1%]. LNG-IUS use was lower in Hispanic women compared with White women [adjusted OR (AOR), 0.7; 95% CI, 0.5–1.0]. Compared with women with ≤high school education, LNG-IUS use was higher for women with ≥college degree (AOR, 2.0; 95% CI, 1.3–3.1). Parous (AOR, 2.6; 95% CI, 1.7–3.9) and insured (AOR, 1.7; 95% CI, 1.0–3.1) women had higher odds of LNG-IUS use, whereas women with diabetes (AOR, 0.3; 95% CI, 0.1–0.7) had lower odds of LNG-IUS use. No differences in LNG-IUS use were observed by endometrial cancer risk factors of women’s body mass index, age of menarche, hypertension, and personal history of cancer. More research is needed to establish the potential benefits of LNG-IUS use on endometrial cancer, which will further highlight potential opportunities for population-level primary prevention to address the growing incidence of endometrial cancer.Prevention Relevance:This study describes the characteristics of American women using the LNG-IUS. Reproductive-age women (especially Hispanic, with lower education, nulliparous, uninsured, and with diabetes) have lower LNG-IUS use odds. These groups may benefit from LNG-IUS use for endometrial cancer primary prevention, conditioned that LNG-IUS use is proven effective in reducing endometrial cancer incidence.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women
Levonorgestrel-releasing intrauterine system (LNG-IUS) use is approved by the FDA for contraception and heavy menorrhagia. More importantly, it effectively treats endometrial hyperplasia, a precursor to endometrial cancer. Therefore, LNG-IUS use is associated with potential endometrial cancer risk reduction, but current use patterns in the United States are unknown. We analyzed LNG-IUS use prevalence among women ages 18 to 50 years using a weighted statistical analysis of the 2017 to 2019 National Survey of Family Growth. Summary statistics were stratified by race and ethnic group and known endometrial cancer sociodemographic and health risk factors and assessed statistically with bivariate Rao–Scott χ2 tests. A multivariable logistic regression model was developed to explore LNG-IUS use predictors. Current LNG-IUS use in the United States was 6.9% [95% confidence interval (CI), 5.9%–8.1%]. LNG-IUS use was lower in Hispanic women compared with White women [adjusted OR (AOR), 0.7; 95% CI, 0.5–1.0]. Compared with women with ≤high school education, LNG-IUS use was higher for women with ≥college degree (AOR, 2.0; 95% CI, 1.3–3.1). Parous (AOR, 2.6; 95% CI, 1.7–3.9) and insured (AOR, 1.7; 95% CI, 1.0–3.1) women had higher odds of LNG-IUS use, whereas women with diabetes (AOR, 0.3; 95% CI, 0.1–0.7) had lower odds of LNG-IUS use. No differences in LNG-IUS use were observed by endometrial cancer risk factors of women’s body mass index, age of menarche, hypertension, and personal history of cancer. More research is needed to establish the potential benefits of LNG-IUS use on endometrial cancer, which will further highlight potential opportunities for population-level primary prevention to address the growing incidence of endometrial cancer.Prevention Relevance:This study describes the characteristics of American women using the LNG-IUS. Reproductive-age women (especially Hispanic, with lower education, nulliparous, uninsured, and with diabetes) have lower LNG-IUS use odds. These groups may benefit from LNG-IUS use for endometrial cancer primary prevention, conditioned that LNG-IUS use is proven effective in reducing endometrial cancer incidence.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S2. Demographic and Clinical Characteristics for Patients Who Underwent Second Look Laparoscopy and Circulating Tumor DNA (ctDNA) Analysis
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S2. Demographic and Clinical Characteristics for Patients Who Underwent Second Look Laparoscopy and Circulating Tumor DNA (ctDNA) Analysis
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S4. Clinical Information of Translational Samples
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S4. Clinical Information of Translational Samples
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S5. Progressively Upregulated or Downregulated Genes in the Tumor Compartment of MRD+ Cases
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S5. Progressively Upregulated or Downregulated Genes in the Tumor Compartment of MRD+ Cases
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S1. CODEX Panel
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S1. CODEX Panel